Earnings Releases·Nov 6, 2026, 8:30 AM ET

CG Oncology — Third Quarter 2026 Earnings Summary

Total revenue declined 3.7% year-over-year to $1.604 million, driven by a $158,000 reduction in license and collaboration revenue, while commercial and development revenue rose to $1.604 million from $1.508 million.
Net loss widened to $56.9 million ($0.64 per share) from $43.8 million ($0.57 per share) in the prior year, primarily due to a 40.5% increase in R&D expenses to $39.2 million.
The company maintains a strong liquidity position with $984.5 million in cash and marketable securities as of September 30, 2026, sufficient to fund operations through 2029.
Key milestones include anticipated PIVOT-006 Phase 3 topline data in November 2026, 12-month data for BOND-003 and CORE-008 in December 2026, and BLA completion for BCG-unresponsive NMIBC in Q4 2026.
Strategic updates include the appointment of Isabel Kalofonos as Chief Commercial Officer in October and the initiation of an Expanded Access Program in North America.